Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Clinical Study to Evaluate the Safety, Tolerance and Initial Efficacy of Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptor T(EGFRvIII CAR-T) in the Treatment of Recurrent Glioblastoma

NCT05802693 is registered in ClinicalTrials.gov with Beijing Tsinghua Chang Gung Hospital as lead sponsor.

NCT NCT05802693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05802693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Clinical Study to Evaluate the Safety, Tolerance and Initial Efficacy of Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptor T(EGFRvIII CAR-T) in the Treatment of Recurrent Glioblastoma
Lead sponsor
Beijing Tsinghua Chang Gung Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
November 15, 2023
Completion date
November 14, 2025
Enrollment
22 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma